a Sanofi company, announced today that the first pediatric patient has
begun treatment in a Phase 1/2 clinical trial focused on evaluating the
investigational therapy olipudase alfa. Olipudase alfa is an enzyme
replacement therapy being studied for the treatment...
a Sanofi company, announced today that the U.S. Food and Drug
Administration (FDA) has granted Breakthrough Therapy designation to
olipudase alfa. This enzyme replacement therapy is being investigated
for the treatment of patients with nonneurological...
a Sanofi company, joins the global multiple sclerosis (MS) community
today in recognition of the seventh annual World MS Day, an initiative
created by the Multiple Sclerosis International Federation (MSIF) to
raise awareness of this devastating disease.
a Sanofi company, announced today that data on its relapsing multiple
sclerosis treatments, Aubagio® (teriflunomide) and
Lemtrada® (alemtuzumab), will be featured during the
2015 annual meeting of the Consortium of Multiple Sclerosis Centers